News Breaks
|
| 09:29 EDT |  | VRX |
| theflyonthewall.com: | Investors may be too bullish on Valeant Pharmaceutical, Barron's says | | Investors may be too optimistic about the potential of Valeant Pharmaceutical's (VRX) epilepsy drug, retigabine, Barron's warns. Retigabine may not be able to compensate for reduced royalties from Valeant's top seller, an antiviral treatment called ribavirin, according to the publication. Meanwhile, Retigabine's side effects caused a large number of patients to withdraw from a clinical study of the drug, Barron's notes. Reference Link :theflyonthewall.com |
|
|
Subscribe for More Information